AURKA promotes cell migration and invasion of head and neck squamous cell carcinoma through regulation of the AURKA/Akt/FAK signaling pathway

The present study aimed to investigate the mechanism by which Aurora kinase A (AURKA) promotes cell migration and invasion in head and neck squamous cell carcinoma (HNSCC). Transwell assays were performed to investigate the cell migration and invasion abilities of AURKA, whilst western blotting was...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2016-03, Vol.11 (3), p.1889-1894
Main Authors: WU, JICHANG, YANG, LIYUN, SHAN, YAMIN, CAI, CHANGPING, WANG, SHILI, ZHANG, HAO
Format: Article
Language:English
Subjects:
Akt
Analysis
Aurora kinase A
Cancer therapies
Care and treatment
Cell adhesion & migration
Cell cycle
Cell division
Cell migration
Cellular signal transduction
Clinical trials
Complications and side effects
FAK
Gene amplification
Head & neck cancer
head and neck squamous cell carcinoma
Immunoglobulins
Kinases
Metastasis
Oncology
Phosphorylation
Proteins
Signal transduction
Squamous cell carcinoma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The present study aimed to investigate the mechanism by which Aurora kinase A (AURKA) promotes cell migration and invasion in head and neck squamous cell carcinoma (HNSCC). Transwell assays were performed to investigate the cell migration and invasion abilities of AURKA, whilst western blotting was used to analyze the protein expression in FaDu and Hep2 cells, each treated with pharmacological inhibitors. Following the inhibition of AURKA, Akt and focal adhesion kinase (FAK), the migration and invasion of the FaDu and Hep2 cells decreased. The expression of phosphorylated (p)-AURKA and p-FAK (Y397) was observed to decrease following FaDu and Hep2 cell treatment with VX-680, a small molecular inhibitor of AURKA. The expression of p-Akt and p-FAK (Y397) ceased following treatment with the Akt inhibitor triciribine. The expression of p-FAK (Y397) decreased, however, p-Akt expression did not change following treatment with the FAK inhibitor TAE226. In conclusion, AURKA activates FAK through the AURKA/Akt/FAK signaling pathway, promoting the migration and invasion of HNSCC cells, which may subsequently provide a novel approach for the treatment of HNSCC.
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2016.4110